Sam Brusco, Associate Editor04.12.23
electroCore has been issued three new patents from the U.S. Patent and Trademark Office (USPTO) relating to the company’s non-invasive vagus nerve stimulation (nVNS) technology.
U.S. Patent Nos. 11,623,079 and 11,623,080 are entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively. The patents relate to nVNS devices and methods to treat addiction and other conditions by releasing dopamine and/or endogenous opioids in the brain.
U.S. Patent No. 11,623,078 is entitled “Devices and Methods for Non-Invasive Vagal Nerve Stimulation.” This patent relates to devices and methods for modulating the vagus nerve by transmitting an electrical impulse transcutaneously through the neck, where the electrical impulse comprises bursts of two to 20 pulses with a frequency of about 10 to 35 Hz.
“electroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” stated Dan Goldberger, CEO of electroCore told the press. “We are focused on exploring ways in which nVNS can help treat a variety of disorders, such as addiction or other dopamine-related conditions, aside from our FDA-cleared use for primary headache.”
In September 2022, electroCore was granted four patents for nVNS and other technologies. The company is also conducting a study with the Mayo Clinic to assess its gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in post-COVID syndrome patients.
U.S. Patent Nos. 11,623,079 and 11,623,080 are entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively. The patents relate to nVNS devices and methods to treat addiction and other conditions by releasing dopamine and/or endogenous opioids in the brain.
U.S. Patent No. 11,623,078 is entitled “Devices and Methods for Non-Invasive Vagal Nerve Stimulation.” This patent relates to devices and methods for modulating the vagus nerve by transmitting an electrical impulse transcutaneously through the neck, where the electrical impulse comprises bursts of two to 20 pulses with a frequency of about 10 to 35 Hz.
“electroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” stated Dan Goldberger, CEO of electroCore told the press. “We are focused on exploring ways in which nVNS can help treat a variety of disorders, such as addiction or other dopamine-related conditions, aside from our FDA-cleared use for primary headache.”
In September 2022, electroCore was granted four patents for nVNS and other technologies. The company is also conducting a study with the Mayo Clinic to assess its gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in post-COVID syndrome patients.